Literature DB >> 18024079

Phenotype of CD4+ T cell subsets that develop following mouse facial nerve axotomy.

Junping Xin1, Derek A Wainwright, Craig J Serpe, Virginia M Sanders, Kathryn J Jones.   

Abstract

We have previously shown that CD4(+) T helper (Th) 2 cells, but not Th1 cells, participate in the rescue of mouse facial motoneurons (FMN) from axotomy-induced cell death. Recently, a number of other CD4(+) T cell subsets have been identified in addition to the Th1 and Th2 effector subsets, including Th17, inducible T regulatory type 1 (Tr1), and naturally thymus-born Foxp3(+) regulatory (Foxp3(+) Treg) cells. These subsets regulate the nature of a T cell-mediated immune response. Th1 and Th17 cells are pro-inflammatory subsets, while Th2, Tr1, and Foxp3(+) Treg cells are anti-inflammatory subsets. Pro-inflammatory responses in the central nervous system are thought to be neurodestructive, while anti-inflammatory responses are considered neuroprotective. However, it remains to be determined if another CD4(+) T cell subset, other than the Th2 cell, develops after peripheral nerve injury and participates in FMN survival. In the present study, we used FACS analysis to determine the temporal frequency of Th1, Th17, Th2, Tr1 and Foxp3(+) Treg CD4(+) T cell subset development in C57BL/6 wild type mice after facial nerve transection at the stylomastoid foramen in the mouse. The results indicate that all of the known CD4(+) T cell subsets develop and expand in number within the draining lymph node, with a peak in number primarily at 7 days postoperative (dpo), followed by a decline at 9 dpo. In addition to the increase in subset frequency over time, FACS analysis of individual cells showed that the level of cytokine expressed per cell also increased for interferon-gamma (IFN-gamma), interleukin (IL)-10 and IL-17, but not IL-4. Additional control double-cytokine labeling experiments were done which indicate that, at 7dpo, the majority of cells indeed have committed to a specific phenotype and express only 1 cytokine. Collectively, our findings indicate for the first time that there is no preferential activation and expansion of any single CD4(+) T cell subset after peripheral nerve injury but, rather, that both pro-inflammatory and anti-inflammatory CD4(+) T cells develop.

Entities:  

Mesh:

Year:  2007        PMID: 18024079      PMCID: PMC2396948          DOI: 10.1016/j.bbi.2007.10.006

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  64 in total

Review 1.  Recruiting the immune response to promote axon regeneration in the injured spinal cord.

Authors:  Samuel David; Shalina S Ousman
Journal:  Neuroscientist       Date:  2002-02       Impact factor: 7.519

2.  Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors.

Authors:  Roberto Furlan; Stefano Pluchino; Peggy C Marconi; Gianvito Martino
Journal:  Methods Mol Biol       Date:  2003

3.  Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.

Authors:  Eiji Nishimura; Toshiko Sakihama; Ruka Setoguchi; Koichi Tanaka; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2004-07-05       Impact factor: 4.823

4.  Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).

Authors:  Terrence Town; Martina Vendrame; Anant Patel; Daniel Poetter; Anthony DelleDonne; Takashi Mori; Robert Smeed; Fiona Crawford; Thomas Klein; Jun Tan; Mike Mullan
Journal:  J Neuroimmunol       Date:  2002-11       Impact factor: 3.478

5.  Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4(+) T cells.

Authors:  Cynthia A Deboy; Junping Xin; Susanna C Byram; Craig J Serpe; Virginia M Sanders; Kathryn J Jones
Journal:  Exp Neurol       Date:  2006-06-27       Impact factor: 5.330

Review 6.  Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system.

Authors:  Guido Stoll; Sebastian Jander; Michael Schroeter
Journal:  Adv Exp Med Biol       Date:  2002       Impact factor: 2.622

7.  CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation.

Authors:  Susanna C Byram; Monica J Carson; Cynthia A DeBoy; Craig J Serpe; Virginia M Sanders; Kathryn J Jones
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

8.  Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor.

Authors:  Iris Lee; Liqing Wang; Andrew D Wells; Martin E Dorf; Engin Ozkaynak; Wayne W Hancock
Journal:  J Exp Med       Date:  2005-04-04       Impact factor: 14.307

9.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.

Authors:  Claire L Langrish; Yi Chen; Wendy M Blumenschein; Jeanine Mattson; Beth Basham; Jonathan D Sedgwick; Terrill McClanahan; Robert A Kastelein; Daniel J Cua
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

10.  Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells.

Authors:  Sayuri Yamazaki; Tomonori Iyoda; Kristin Tarbell; Kara Olson; Klara Velinzon; Kayo Inaba; Ralph M Steinman
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

View more
  21 in total

1.  Age and facial nerve axotomy-induced T cell trafficking: relation to microglial and motor neuron status.

Authors:  Daniel J Dauer; Zhi Huang; Grace K Ha; Jeremy Kim; David Khosrowzadeh; John M Petitto
Journal:  Brain Behav Immun       Date:  2010-08-19       Impact factor: 7.217

Review 2.  Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury.

Authors:  D P Ankeny; P G Popovich
Journal:  Neuroscience       Date:  2008-07-04       Impact factor: 3.590

3.  Use of laser microdissection in the investigation of facial motoneuron and neuropil molecular phenotypes after peripheral axotomy.

Authors:  Nichole A Mesnard; Thomas D Alexander; Virginia M Sanders; Kathryn J Jones
Journal:  Exp Neurol       Date:  2010-06-04       Impact factor: 5.330

Review 4.  CD4 + T Cells and Neuroprotection: Relevance to Motoneuron Injury and Disease.

Authors:  Kathryn J Jones; Amy E Lovett-Racke; Chandler L Walker; Virginia M Sanders
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-07       Impact factor: 4.147

5.  Differential gene expression in the axotomized facial motor nucleus of presymptomatic SOD1 mice.

Authors:  Nichole A Mesnard; Virginia M Sanders; Kathryn J Jones
Journal:  J Comp Neurol       Date:  2011-12-01       Impact factor: 3.215

6.  Immune cell-mediated neuroprotection is independent of estrogen action through estrogen receptor-alpha.

Authors:  Junping Xin; Keith N Fargo; Lisa Tanzer; Virginia M Sanders; Kathryn J Jones
Journal:  Metab Brain Dis       Date:  2012-03       Impact factor: 3.584

7.  The expression of IL-2 and IL-4 in CD4(+) T cells from mouse lymph nodes and spleen during HSV-1-induced facial palsy.

Authors:  Lintao Gu; Yuechen Han; Wenwen Liu; Yanyan Mao; Jianfeng Li; Haibo Wang
Journal:  Inflamm Res       Date:  2013-11-27       Impact factor: 4.575

8.  Functional recovery and facial motoneuron survival are influenced by immunodeficiency in crush-axotomized mice.

Authors:  Taylor Beahrs; Lisa Tanzer; Virginia M Sanders; Kathryn J Jones
Journal:  Exp Neurol       Date:  2009-11-11       Impact factor: 5.330

9.  CD4+ T cell-mediated neuroprotection is independent of T cell-derived BDNF in a mouse facial nerve axotomy model.

Authors:  Junping Xin; Nichole A Mesnard; Taylor Beahrs; Derek A Wainwright; Craig J Serpe; Thomas D Alexander; Virginia M Sanders; Kathryn J Jones
Journal:  Brain Behav Immun       Date:  2012-03-07       Impact factor: 7.217

10.  Exacerbation of facial motoneuron loss after facial nerve axotomy in CCR3-deficient mice.

Authors:  Derek A Wainwright; Junping Xin; Nichole A Mesnard; Taylor R Beahrs; Christine M Politis; Virginia M Sanders; Kathryn J Jones
Journal:  ASN Neuro       Date:  2009-12-11       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.